Universal Beteiligungs und Servicegesellschaft mbH Takes Position in Alkermes plc (NASDAQ:ALKS)

Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Alkermes plc (NASDAQ:ALKS - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 113,818 shares of the company's stock, valued at approximately $3,273,000. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.07% of Alkermes as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the company. RTW Investments LP increased its holdings in shares of Alkermes by 13.6% in the fourth quarter. RTW Investments LP now owns 7,557,835 shares of the company's stock worth $217,363,000 after purchasing an additional 903,802 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of Alkermes by 1.1% in the fourth quarter. Renaissance Technologies LLC now owns 5,478,728 shares of the company's stock worth $157,568,000 after purchasing an additional 57,697 shares during the last quarter. American Century Companies Inc. increased its holdings in shares of Alkermes by 6.5% in the fourth quarter. American Century Companies Inc. now owns 3,450,707 shares of the company's stock worth $99,242,000 after purchasing an additional 209,740 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Alkermes by 4.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 3,019,508 shares of the company's stock worth $86,842,000 after purchasing an additional 128,701 shares during the last quarter. Finally, Avoro Capital Advisors LLC purchased a new position in Alkermes in the fourth quarter worth about $70,462,000. 95.21% of the stock is owned by institutional investors.

Alkermes Stock Performance

NASDAQ ALKS traded up $0.71 during trading on Friday, hitting $31.71. The stock had a trading volume of 1,125,369 shares, compared to its average volume of 1,742,562. The stock has a market capitalization of $5.23 billion, a price-to-earnings ratio of 14.61, a P/E/G ratio of 2.20 and a beta of 0.47. Alkermes plc has a one year low of $22.90 and a one year high of $36.45. The stock has a 50 day simple moving average of $29.62 and a 200 day simple moving average of $30.94.

Alkermes (NASDAQ:ALKS - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported $0.13 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.19). Alkermes had a net margin of 23.57% and a return on equity of 30.80%. The company had revenue of $306.51 million for the quarter, compared to the consensus estimate of $307.53 million. During the same period in the prior year, the firm posted $0.43 EPS. The business's revenue was down 12.6% on a year-over-year basis. On average, sell-side analysts predict that Alkermes plc will post 1.31 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on ALKS shares. Cantor Fitzgerald upgraded Alkermes to a "strong-buy" rating in a research report on Tuesday, May 13th. Robert W. Baird lifted their price target on Alkermes from $38.00 to $41.00 and gave the stock an "outperform" rating in a research report on Friday, May 2nd. Royal Bank of Canada lifted their price target on Alkermes from $39.00 to $40.00 and gave the stock a "sector perform" rating in a research report on Friday, May 2nd. HC Wainwright reiterated a "neutral" rating on shares of Alkermes in a research report on Friday, May 2nd. Finally, Needham & Company LLC started coverage on Alkermes in a research report on Wednesday, May 28th. They issued a "buy" rating and a $45.00 price target for the company. Four research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $38.85.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.